Tirzepatide (Mounjaro/Zepbound) Sales Projections
- Conservative Projection
- Optimistic Projection
Key Analyst Projections:
- UBS: Estimates peak sales of $25 billion for Mounjaro
- Bank of America: Projects annual sales could hit $48 billion
- GlobalData: Forecasts $27 billion by 2029 for Mounjaro, $27.2 billion by 2030 for Zepbound
- Goldman Sachs: Projects global anti-obesity market at $100 billion by 2030
- EvaluatePharma: Projects $17 billion in sales by 2028
0